Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Parenteral and Enteral Nutrition
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mangian, H. F.
Right arrow Articles by Tappenden, K. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mangian, H. F.
Right arrow Articles by Tappenden, K. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

2009 Harry M. Vars Research Award

Butyrate Increases GLUT2 mRNA Abundance by Initiating Transcription in Caco2-BBe Cells

Heather F. Mangian, MS1 and Kelly A. Tappenden, PhD, RD1,2

From the 1 Division of Nutritional Sciences and2 Department of Food Science and Human Nutrition, University of Illinois at Champaign-Urbana, Urbana, Illinois.

Address correspondence to: Kelly A. Tappenden, PhD, RD, University of Illinois, 443 Bevier Hall, 905 S. Goodwin Avenue, Urbana, IL 61801; e-mail: tappende{at}illinois.edu.

Background: Glucose transporter 2 (GLUT2) is a high-capacity, facilitative intestinal monosaccharide transporter, known to be upregulated by short-chain fatty acids (SCFAs) derived from the intestinal microbiota during fermentation. Understanding the mechanisms regulating intestinal function is important to optimize therapies for patients with intestinal failure and ultimately reduce their dependence on parenteral nutrition. Objective: The objective was to examine the mechanism regulating the underlying response of GLUT2 to the SCFA butyrate. Methods: GLUT2 messenger RNA (mRNA) abundance was measured in differentiated Caco2-BBe monolayers treated for 0.5-24 hours with 0-20 mM butyrate using quantitative reverse transcription–polymerase chain reaction. Activation of the human GLUT2 promoter was measured using luciferase reporting in transiently transfected Caco2-BBe monolayers. Results: GLUT2 mRNA abundance was higher (P < .0001) with 1-4 hours of exposure to 2.5, 7.5, and 10 mM butyrate. Butyrate induced (P < .0001) promoter activity in a dose-dependent fashion. Analysis of the GLUT2 promoter indicated that regions –282/+522, –216/+522, and –145/+522 had a heightened (P < .05) response to butyrate compared with 1135/+522 and 564/+522. Conclusions: Butyrate upregulates GLUT2 mRNA abundance in Caco2-BBe monolayers by activating specific regions within the human GLUT2 promoter. These results identify a cellular mechanism wherein butyrate upregulates intestinal absorption that may be relevant to patients with reduced function. Additional work is necessary to understand cellular targets of butyrate therapy and define clinically appropriate means of providing such strategies, such as consuming prebiotics and probiotics.

Key Words: butyrate


 

Discussant Questions and Author Response

Journal of Parenteral and Enteral Nutrition, Vol. 33, No. 6, 607-617 (2009)
DOI: 10.1177/0148607109336599


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?